[Surfactant therapy in severe neonatal respiratory failure--multicenter study--I. Surfactant therapy in 264 premature infants of < 34 weeks with IRDS with special reference to "non-responders"].
As a part of a west german multicenter study (16 hospitals) 264 preterm neonates < 34 gestational weeks were treated with bovine surfactant (Alveofact, 50-200 mg/kgBW). Entry criterion was need of mechanical ventilation and FiO2 of > 0.5. Compared with a previous prophylactic study with the same surfactant product these patients were slightly more mature (median: 29 gestational weeks, 1260 g) but had a higher oxygen demand at the time of treatment (median FiO2: 0.82). Survival rate (28. d) was 82%. At this time 38% showed spontaneous respiration without, 16% with additional oxygen. The incidence of pulmonary interstitial emphysema was 22%, of pneumothorax 13%, and of PDA 33%. Severe intracranial hemorrhage (grade III or IV according to Papile) had 25%, ROP (any grade) 27%. Nonresponder showed a higher initial FiO2 of 0.94. With regard to umbilical artery pH, mode of delivery, birth weight, and maturity) they were similar to the responders. We did not find a parameter, by which we could predict the response to surfactant.
Ebbecke
K
K
Universitätskinderklinik Münster.
Jorch
G
G
D005260:Female; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D008055:Lipids / Q000008:administration & dosage*; D008297:Male; D010100:Oxygen / Q000097:blood; D010743:Phospholipids; D011379:Prognosis; D011663:Pulmonary Surfactants / Q000008:administration & dosage*; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000097:blood / Q000628:therapy*
D008055:Lipids; D010743:Phospholipids; D011663:Pulmonary Surfactants; C078272:SF-RI 1, bovine surfactant preparation; D010100:Oxygen
Surfactanttherapie bei schwerer neonataler Ateminsuffizienz--Multizentrische Studie--I. Surfactanttherapie bei 264 Frühgeborenen < 34 SSW mit IRDS unter besonderer Berücksichtigung der "Nonresponder".